SCHEMBL105602

SCHEMBL105602

CC(C)NC(C)C(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9913298 1.00 TDP1 (0.47) TDP1
SCHEMBL276661 0.85 TDP1 (0.33) TDP1
SCHEMBL13075675 0.73 GAA (0.32) TDP1
SCHEMBL7961098 0.73 CYP3A4 (0.34)
SCHEMBL21843930 0.73 TDP1 (0.41) TDP1
SCHEMBL18467862 0.73
SCHEMBL13937735 0.73 TDP1 (0.41) TDP1
SCHEMBL21448478 0.73 TDP1 (0.41) TDP1
SCHEMBL13080667 0.71 TDP1 (0.47) TDP1
SCHEMBL16746700 0.71 TDP1 (0.47) TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230399538-A1 POLYUREA COPOLYMER COATING COMPOSITIONS AND METHODS INNOVATIVE SURFACE TECHNOLOGIES, INC. 2023-12-14 US disclosed
US-11781035-B2 Polyurea copolymer coating compositions and methods INNOVATIVE SURFACE TECHNOLOGIES, INC. (US) 2023-10-10 US disclosed
US-20230241287-A1 SILICONE POLYUREA BLOCK COPOLYMER COATING COMPOSITIONS AND METHODS INNOVATIVE SURFACE TECH INC (US) 2023-08-03 US disclosed
US-20230241287-A1 SILICONE POLYUREA BLOCK COPOLYMER COATING COMPOSITIONS AND METHODS INNOVATIVE SURFACE TECH INC (US) 2023-08-03 US disclosed
US-11672884-B2 Silicone polyurea block copolymer coating compositions and methods INNOVATIVE SURFACE TECHNOLOGIES, INC. (US) 2023-06-13 US disclosed
US-11672884-B2 Silicone polyurea block copolymer coating compositions and methods INNOVATIVE SURFACE TECHNOLOGIES, INC. (US) 2023-06-13 US disclosed
US-11247179-B2 Method of preparing membranes APPLIED BIOMIMETIC A/S (DK) 2022-02-15 US disclosed
US-20200405909-A1 SILICONE POLYUREA BLOCK COPOLYMER COATING COMPOSITIONS AND METHODS INNOVATIVE SURFACE TECHNOLOGIES, INC. (US) 2020-12-31 US disclosed
US-10544358-B2 Coated and cured proppants PREFERRED TECHNOLOGY, LLC (US) 2020-01-28 US disclosed
US-10208242-B2 Proppant with polyurea-type coating PREFERRED TECHNOLOGY, LLC (US) 2019-02-19 US disclosed
US-7329663-B2 Substituted-triazolopyrimidines as anticancer agents WYETH (US) 2008-02-12 US disclosed
US-20070232549-A1 Novel peptides as NS3-serine protease inhibitors of hepatitis C virus SCHERING CORPORATION 2007-10-04 US disclosed
US-7244721-B2 Peptides as NS3-serine protease inhibitors of hepatitis C virus SCHERING CORPORATION (US) 2007-07-17 US disclosed
US-20070142301-A1 Novel inhibitors of Hepatitis C virus NS3 protease MERCK SHARP & DOHME CORP. 2007-06-21 US disclosed
US-20070093430-A1 Novel ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus MERCK SHARP & DOHME CORP. 2007-04-26 US disclosed
US-7205330-B2 Inhibitors of hepatitis C virus NS3 protease SCHERING CORPORATION (US) 2007-04-17 US disclosed
US-20070042968-A1 Sulfur compounds as inhibitors of Hepatitis C virus NS3 serine protease SCHERING CORPORATION 2007-02-22 US disclosed
US-20070032433-A1 Novel peptides as NS3-serine protease inhibitors of hepatitis C virus SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. 2007-02-08 US disclosed
US-7173057-B2 Ketoamides with cyclic P4'S as inhibitors of NS3 protease of hepatitis C virus SCHERING CORPORATION (US) 2007-02-06 US disclosed
WO-2005030796-A1 MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE SCHERING CORPORATION (US) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232549-A1 Novel peptides as NS3-serine protease inhibitors of hepatitis C virus HPN, TMPRSS15, VIP TDP1 3248/4885
US-20070142301-A1 Novel inhibitors of Hepatitis C virus NS3 protease HAVCR2, RNASE1, SERPINB1 TDP1 2686/4885
US-20070093430-A1 Novel ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus PREP, PRSS1, P4HB TDP1 3327/4885
US-20070032433-A1 Novel peptides as NS3-serine protease inhibitors of hepatitis C virus HPN, TMPRSS15, VIP TDP1 3248/4885
US-20070042968-A1 Sulfur compounds as inhibitors of Hepatitis C virus NS3 serine protease PRSS1, PRSS3, HPN TDP1 3667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.